- Home
- MPU vs GBIO Comparison
MPU vs GBIO Comparison
Compare MPU & GBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MPU
- GBIO
- Stock Information
- Founded
- MPU 1989
- GBIO 2016
- Country
- MPU Singapore
- GBIO United States
- Employees
- MPU N/A
- GBIO N/A
- Industry
- MPU Transportation Services
- GBIO Biotechnology: Pharmaceutical Preparations
- Sector
- MPU Consumer Discretionary
- GBIO Health Care
- Exchange
- MPU Nasdaq
- GBIO Nasdaq
- Market Cap
- MPU 43.5M
- GBIO 35.2M
- IPO Year
- MPU 1998
- GBIO 2020
- Fundamental
- Price
- MPU $0.68
- GBIO $0.37
- Analyst Decision
- MPU
- GBIO Strong Buy
- Analyst Count
- MPU 0
- GBIO 4
- Target Price
- MPU N/A
- GBIO $7.33
- AVG Volume (30 Days)
- MPU 121.3K
- GBIO 447.7K
- Earning Date
- MPU 05-07-2025
- GBIO 03-13-2025
- Dividend Yield
- MPU N/A
- GBIO N/A
- EPS Growth
- MPU N/A
- GBIO N/A
- EPS
- MPU N/A
- GBIO N/A
- Revenue
- MPU $36,184,000.00
- GBIO $19,892,000.00
- Revenue This Year
- MPU N/A
- GBIO N/A
- Revenue Next Year
- MPU N/A
- GBIO $10.90
- P/E Ratio
- MPU N/A
- GBIO N/A
- Revenue Growth
- MPU 75598.74
- GBIO 236.92
- 52 Week Low
- MPU $0.49
- GBIO $0.37
- 52 Week High
- MPU $2.99
- GBIO $4.52
- Technical
- Relative Strength Index (RSI)
- MPU 46.03
- GBIO 27.19
- Support Level
- MPU $0.60
- GBIO $0.48
- Resistance Level
- MPU $0.71
- GBIO $0.50
- Average True Range (ATR)
- MPU 0.08
- GBIO 0.05
- MACD
- MPU 0.03
- GBIO 0.00
- Stochastic Oscillator
- MPU 79.55
- GBIO 3.11
About MPU Mega Matrix Corp.
Mega Matrix Inc formerly Mega Matrix Inc is a holding company. It operates through its two subsidiaries Mega Metaverse Corp (Mega) and JetFleet Management Corp (JMC). The Company has two business segments which are comprised of : ETH staking business and The leasing of regional aircraft to foreign and domestic regional airlines. The majority of the company's revenue is earned through Leasing business segment.
About GBIO Generation Bio Co.
Generation Bio Co is a genetics medicine company that is focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable highly differentiated therapeutic applications. Its first platform is a potent, highly selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.